Securities Class Action Filed on Behalf of Persons or Entities That Traded Certain Derivative Securities of Allergan, Inc. During the Period February 25, 2014 Through April 21, 2014, Inclusive

June 30, 2017

Entwistle & Cappucci LLP (“Entwistle & Cappucci”) and Susman Godfrey L.L.P. (“Susman Godfrey”) today announced that they have filed a securities class action lawsuit on behalf of persons or entities that traded certain derivative securities of Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) during the period February 25, 2014 through April 21, 2014, inclusive (the “Class Period”), and who thereby sustained damages (the “Class”).  The case was filed in the United States District Court for the Central District of California, Case No. CV 17-04776-DOC (KESx), against Pershing Square Capital Management, L.P., Valeant Pharmaceuticals International, Inc. (“Valeant”) and related defendants (collectively, “Defendants”).

The class action asserts claims under Sections 14(e), 20A and 20(a) of the Securities Exchange Act of 1934 arising from the 2014 attempted acquisition of Allergan by Valeant and its affiliates.  The complaint alleges that certain Defendants traded on material non-public information regarding the proposed acquisition, and as a result, Class members that sold Allergan call options, purchased Allergan put options and/or sold Allergan equity forward contracts during the Class Period did so at prices that did not reflect the material nonpublic information known to Defendants.  In this action, Plaintiff seeks an award of damages, and prejudgment interest, to Plaintiff and other Class members.

If you wish to serve as a lead plaintiff in this matter, you must file a motion with the Court no later than 60 days from today, or by August 29, 2017.  Any member of the proposed Class may move the Court to serve as a lead plaintiff in this matter through counsel of their choice, or they may choose to do nothing and remain a member of the Class.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact:  Andrew J. Entwistle, Esq. of Entwistle & Cappucci at (212) 894-7200 or via e-mail at [email protected]; or Robert N. Cappucci, Esq. of Entwistle & Cappucci at (212) 894-7200 or via e-mail at [email protected].

About Entwistle & Cappucci

Entwistle & Cappucci is a national law firm providing exceptional legal representation to clients globally in the most complex and challenging legal matters.  Our practice encompasses all areas of litigation, including securities, antitrust, corporate transactions, general corporate and commercial, creditor’s rights and bankruptcy, corporate governance and fiduciary duty, government affairs, insurance, investigations and white collar defense.  Our clients include public and private corporations, major hedge funds, public pension funds, governmental entities, leading institutional investors, domestic and foreign financial services companies, emerging business enterprises and individual entrepreneurs.

About Susman Godfrey

For more than 30 years, Susman Godfrey has focused its nationally recognized practice on just one thing:  high-stakes commercial litigation.  It is one of the nation’s leading law firms, with offices in Houston, Seattle, Los Angeles and New York.  For more information, visit www.susmangodfrey.com.

CONTACT:  Entwistle & Cappucci LLP
Robert N. Cappucci, Esq. ([email protected])
299 Park Avenue, 20th Floor
New York, New York 10171
Telephone:  (212) 894-7200
Facsimile:  (212) 894-7272
www.entwistle-law.com